Issue link: http://osercommunicationsgroup.uberflip.com/i/668581
C h a i n D r u g s t o r e D a i l y 3 3 M o n d a y, A p r i l 1 8 , 2 0 1 6 aren't going to outspend our competition, so we focus on being more unique, more creative and more approachable. Every interaction someone has with hello is authentic, fun, friendly and memorable. We set out to make products that are effective, delicious and beautiful, and as natural as we can make them. We don't use artificial sweeteners, dyes, microbeads, preservatives or triclosan, but we do use high-quality ingredients like xylitol from non-GMO corn and sus- tainably harvested stevia. What's more, all hello products are packaged in BPA- free tubes and made in the U.S.A. They're gluten-free, vegan and aren't tested on animals – and we have the certifications and recognition from groups like PETA and Leaping Bunny to prove it. CDD: What trends are driving the oral care category? CD: It's no secret there's been a surge of consumer interest beyond basic cavity protection. Whitening is becoming cost of entry, especially for younger people. We are also seeing heightened focus on sensitivity. Of course, people today are much more attuned to where their prod- ucts come from and what they're made of. People are looking for more natural ingredients and great design. The oral care category isn't fully delivering on those dimensions, which we see as a huge opportunity for a nimble and authentic brand like hello. CDD: What are the most significant innovations affecting the oral care cate- gory right now? hello (C o nt'd. fro m p. 1 ) CD: It's about giving people both what they need but also what they desire – functional and cosmetic benefits, natural and sustainable ingredients they can feel good about giving to their family, and also something that looks great. But it's not just about product innovation. People want to feel an emotional con- nection to the brands they buy and believe in the people that stand behind those brands. hello is a tight-knit group of passionate professionals and we're thrilled to bring some fun and friendly to the category. CDD: What's hello working on present- ly? CD: We respect a brusher's right to choose, and with that in mind, we recent- ly launched SLS-free and fluoride-free adult and kids paste. We've added aloe vera, erythritol and xylitol to both pastes to help clean and whiten. Our adult ver- sion features a natural sweet mint flavor, and our kids' version has a natural water- melon flavor that's safe for toddlers who often haven't perfected their ability to spit just yet. We're also excited to have launched our new extra whitening paste with no peroxide. It uses a very gentle silica and calcium carbonate to safely and gently remove stains. Like all of our pastes, it tastes amazing. We're actively working on new products, so stay tuned. It's an exciting time at hello! For more information, contact Kim Sines by emailing kim@hello-products.com or calling 201.310.3354. insights, Mars Chocolate North America delivers a mouthwatering line- up of innovative products. Here's what's trending – and tasty – in the candy aisle: "Better-for-You" Mars is expanding its product portfolio to include a range of innovative snack- ing options to meet consumers' goals for health and wellness. For example, new goodnessknows ® snack squares and DOVE ® Chocolate Fruit & Nut are made with delicious dark chocolate, real fruits and nuts. Shoppers seeking snacks that are under 200 calories per serving can enjoy goodnessknows snack squares, as well as new SNICK- ERS ® Crisper and M&M'S ® Crispy Candies. Crispy and Crunchy Another trend is consumers' desire for new textures. It's resulted in the creation of a new Crispy Crunchy Segment with- in the Chocolate Category. To meet this demand, Mars Chocolate launched M&M'S Crispy Candies and SNICKERS Crisper. Introduced in late 2015, SNICK- ERS Crisper is a delicious combination of crisped rice and peanuts topped with a layer of caramel and coated in creamy milk chocolate. Seasonal is a Perennial Best Seller In the drug channel, seasonal candy rep- resents 40 percent of confectionery sales. Especially popular right now: seasonal shapes in both singles and sharing sizes, like TWIX ® Hearts and Eggs, and SNICKERS Pumpkins and Trees. To complement its ever-popular sea- sonal shapes, Mars is rolling out a host of Mars (C o nt'd. fro m p. 1 ) new holiday items, including: Easter 2016: M&M'S Speckled Malt Mini Chocolate Eggs, SNICKERS Minis Filled Cane with bunny ears on top, and DOVE Chocolate Bunnies and Chicks Halloween 2016: M&M'S Milk Chocolate Crispy S'mores Candies, DOVE Milk Chocolate in a new "treat size" that are perfect for trick-or-treating, DOVE Dark Chocolate Jack-O-Lanterns and variety bags filled with "Crunchy & Crispy" and "Smooth & Creamy" offer- ings from TWIX, SNICKERS, 3 MUS- KETEERS ® , DOVE and MILKY WAY ® brands. Christmas 2016: SNICKERS and MILKY WAY Bites packaged in an ornament pouch, TWIX Brand Minis Cane for the Holidays and a beautiful gift box filled with DOVE Brand PROMISES ® Silky Smooth Milk Chocolate. Smaller Portions Are Big Demand for portion control continues to grow, spurring explosive growth in the unwrapped, bite-sized candy category. Consumers are seeking the full taste experience of their favorite candy bars in bite-size portions. Mars now offers six varieties: SNICKERS Bites, MILKY WAY Bites, MILKY WAY Simply Caramel Bites, TWIX Bites, 3 MUSKETEERS Bites and 3 MUSKETEERS Mint Bites. In addition to offering iconic chocolate brands, Mars also helps retailers drive category sales with best-in-class mer- chandising, packaging and consumer promotions. Visit Mars at booth #226. For more information, visit www.mars.com or call 800.631.7630. improve specialty generics manufactur- ing at its St. Louis site. Completion of the over $50 million project is expected in 2017 and will allow the company to mod- ernize the manufacturing of key prod- ucts. Mallinckrodt is a substantial provider of many controlled substances delivered to the active pharmaceutical ingredient (API) market, and enhanced availability of the company's APIs and multisource – or specialty generic – prod- ucts will be significant for customers. "By investing in new infrastructure, we can introduce more innovative equip- ment and processes that help us prepare to continue to meet regulatory requirements as well as the needs of our customers," said Frank Scholz, Senior Vice President of Global Operations. "As new technolo- gies are introduced, Mallinckrodt will be able to modify existing drug formulations and continue to provide quality medica- tions for patients." Mallinck ro dt (C o nt'd. fro m p. 1 ) At Mallinckrodt's Hobart, N.Y. plant, new packaging line equipment has helped improve equipment flexibility; the Hobart plant has also invested in the latest tablet press technology that helps make production more efficient and increases capacity for products in the development pipeline. Other investments across the company's plant network include system upgrades at the compa- ny's plant in Raleigh, North Carolina. For Walt Kaczmarek, Mallinckrodt's Vice President and President, Multisource Pharmaceuticals, these investments represent how Mallinckrodt views its relationship with customers as a strategic partner – not just a supplier. He says, "Mallinckrodt remains focused on staying customer-centric, demonstrating our commitment to our values and main- taining investments in our operations." Visit Mallinckrodt Pharmaceuticals at booth #318. For more information, call 800.325.8888 or go to www.mallinckrodt.com. ANTHERA PHARMACEUTICALS ANNOUNCES APPOINTMENT OF INTERIM CHIEF MEDICAL OFFICER Anthera Pharmaceuticals, Inc. has announced the appointment of James Pennington, M.D. as interim Chief Medical Officer following the company's acceptance of Colin Hislop's resignation effective April 1st, 2016. "Our development programs have progressed extensively during Colin's tenure at Anthera, and during that time, both blisibimod and Sollpura ® have advanced into late-stage clinical trials. We thank Colin for his contributions to that development progress and wish him much success in his future endeavors," said Craig Thompson, Anthera's President and Chief Operating Officer. "Jim's long history at Anthera and sub- stantial experience with our clinical pro- grams, combined with his successful reg- ulatory and commercialization experi- ence, will continue to play a pivotal role in keeping our development programs on track for achievement of our milestones in 2016." Dr. Pennington assumes the posi- tion of interim Chief Medical Officer with more than 40 years of successful clinical development and commercial- ization, including 14 drug approvals and 10 registration ex-US approvals includ- ing both small and large molecule thera- peutics. "Working with the dedicated med- ical team at Anthera has been gratifying and I am privileged to lead our devel- opment efforts as interim Chief Medical Officer," said Dr. Pennington. "As we continue the final stages of our clinical programs, I am confident in our team's ability to bring new treatment options to patients with unmet medical needs." Dr. Pennington joined Anthera in 2007 as Executive Vice President and Chief Medical Officer and transitioned to Senior Clinical Fellow in 2010. Prior to joining Anthera in 2007, Dr. Pennington served as Executive Vice President and Chief Medical Officer of CoTherix where he oversaw the approval of Ventavis ® . He previously served as Chief Medical Officer of InterMune as well as in a variety of positions at early stage biotech compa- nies and large global pharmaceutical companies including Alpha Therapeutic Corporation, Shaman Pharmaceuticals and Bayer Corporation. Dr. Pennington spent 12 years as a member of the Harvard Medical School faculty. Dr. Pennington holds a B.A. from the University of Oregon and an M.D. from the University of Oregon Medical School and is Board Certified in internal medicine and infectious diseases. About Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals is a clinical- stage biopharmaceutical company focused on developing and commercial- izing products to treat serious and life- threatening diseases, including exocrine pancreatic insufficiency due to cystic fibrosis, lupus, lupus with glomeru- lonephritis, and IgA nephropathy. For more information, visit www.anthera.com.